Amarin Plcuk Quick Ratio (AMRN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amarin Corp Plcuk  (NASDAQ: AMRN)

Amarin Plcuk's Quick Ratio

AMRN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.85 below Amarin Corp Plcuk average.

Within Major Pharmaceutical Preparations industry 291 other companies have achieved higher Quick Ratio than Amarin Plcuk in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 499 to 1443.

Explain Quick Ratio?
How much Cash & cash equivalents AMRN´s has?
What are AMRN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AMRN/financial-strength
https://api.csimarket.com/api/v1/companies/AMRN/fundamentals
https://api.csimarket.com/api/v1/companies/AMRN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AMRN Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 377.05 %
Y / Y Cash & cash equivalent Change 12.72 %
Quick Ratio MRQ 1.85
AMRN's Total Ranking # 1443
Seq. Current Liabilities Change 6.66 %
Seq. Cash & cash equivalent Change 2.71 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 292
Healthcare Sector # 509
Overall Market # 1443


Quick Ratio Statistics
High Average Low
68.11 5.93 0.54
(Jun 30 2011)   (Sep 30 2018)




Financial Statements
Amarin Plcuk's Current Liabilities $ 175 Millions Visit AMRN's Balance sheet
Amarin Plcuk's Cash & cash equivalent $ 323 Millions Visit AMRN's Balance sheet
Source of AMRN's Sales Visit AMRN's Sales by Geography


Cumulative Amarin Plcuk's Quick Ratio

AMRN's Quick Ratio for the trailling 12 Months

AMRN Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 139.73 %
Y / Y Cash & cash equivalent TTM Growth 7.44 %
Quick Ratio TTM 2.75
Total Ranking TTM # 3996
Seq. Current Liabilities TTM Growth 43.95 %
Seq. Cash & cash equivalent TTM Growth 3.01 %

Quick ratio ranking by company, industry and sector >> Back to AMRN Financial Strength Comparisons >> Go to Compare AMRN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $175.14 millions, cumulative Quick Ratio decreased to 2.75 below the Amarin Corp Plcuk average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Amarin Plcuk. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2831 to 3996.

Explain Quick Ratio?
How much Cash & cash equivalents AMRN´s has?
What are AMRN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 900
Within the Market # 3996


trailing twelve months Quick Ratio Statistics
High Average Low
21.95 3.04 0.65
(Mar 31 2012)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Gain Therapeutics inc  4.94 $ 11.698  Millions$ 2.369  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Mereo Biopharma Group Plc  4.75 $ 26.097  Millions$ 5.494  Millions
Spruce Biosciences Inc   4.69 $ 87.691  Millions$ 18.710  Millions
Septerna Inc   4.56 $ 478.601  Millions$ 104.863  Millions
Atossa Therapeutics Inc   4.37 $ 20.574  Millions$ 4.709  Millions
Neurogene Inc   4.35 $ 78.942  Millions$ 18.163  Millions
Entrada Therapeutics Inc   4.34 $ 112.302  Millions$ 25.863  Millions
Gyre Therapeutics Inc   4.34 $ 86.190  Millions$ 19.874  Millions
Cellectar Biosciences Inc   4.24 $ 24.582  Millions$ 5.798  Millions
Foghorn Therapeutics Inc   4.19 $ 156.222  Millions$ 37.315  Millions
Calcimedica Inc   4.12 $ 13.768  Millions$ 3.339  Millions
Revelation Biosciences Inc   3.92 $ 9.122  Millions$ 2.328  Millions
Tonix Pharmaceuticals Holding Corp   3.87 $ 162.793  Millions$ 42.026  Millions
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Xilio Therapeutics Inc   3.47 $ 122.182  Millions$ 35.258  Millions
Corbus Pharmaceuticals Holdings Inc   3.30 $ 115.337  Millions$ 34.967  Millions
Maia Biotechnology Inc   3.30 $ 21.339  Millions$ 6.474  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Nextcure Inc   2.95 $ 8.728  Millions$ 2.960  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions

Date modified: 2026-11-10T11:27:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.